Navigation Links
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
Date:3/5/2012

SAN DIEGO, March 5, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its fourth quarter and full year ended December 31, 2011 financial results on Monday, March 12, 2012.

Cadence management will host a conference call and live webcast to discuss the financial results on Monday, March 12, 2012 at 1:30 pm Pacific Time (4:30 pm Eastern Time). Interested investors may participate in the conference call by dialing (877) 303-9145 (domestic) or (760) 536-5203 (international).  To access the webcast, please visit the company's website at www.cadencepharm.com and go to the Investor Relations page.  A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call.

About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting.  For more information about Cadence, please visit www.cadencepharm.com.

 Contacts:

William R. LaRue 

SVP & Chief Financial Officer 

Cadence Pharmaceuticals, Inc. 

858-436-1400


'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Credit Suisse Healthcare Conference on November 9, 2011
2. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2011 Financial Results on August 3, 2011
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results on March 4, 2011
4. Cadence Pharmaceuticals Announces U.S. Launch and Availability of OFIRMEV™ (acetaminophen) Injection
5. Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results on November 5, 2009
7. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of September 2009
8. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
9. Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
10. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
11. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... DUBLIN , July 24, 2014 ... the "Global Cell Culture Market 2014-2018" report ... Cell culture is the in vitro ... such as research, cell studies, and biopharmaceutical production. Cell ... vaccine production. Cell culture instruments and cell culture consumables ...
(Date:7/24/2014)... Your cell phone may stay charged ... storage capacity. , New research indicates that lithium-ion ... at Lawrence Livermore National Laboratory and ... components will perform as electrodes. , The growing ... for higher-performance batteries. Several key characteristics of lithium-ion ...
(Date:7/24/2014)...  CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical ... for the prevention and treatment of cardiorenal and ... July 18, 2014 from the NYSE MKT LLC ... plan to regain compliance with continued listing standards ... is continuing the Company,s listing and has granted ...
(Date:7/24/2014)... 2014 2014 Deep Research Report ... a professional and in-depth research report on Potassium ... basic information, including its definition, classification, application, ... research covers the international market analysis, including China’s ... covering macroeconomic environment & economic situation analysis, the ...
Breaking Biology Technology:Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2Getting More Life out of Lithium-ion Batteries 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4
... , , ROCKVILLE, Md., ... has announced that 263 regulatory professionals achieved Regulatory Affairs ... RAC credential is administered by RAPS and is the ... product sector. , , (Logo: ...
... BEIJING, Sept. 4 /PRNewswire-Asia/ -- ... provider of biopharmaceutical products in China, announced today that,the ... Republic,of China has issued the initial order to Sinovac ... to the initial order, Sinovac is,required to complete the ...
... September 4 Karolinska Development (publ),today announced that one ... clinical study of its candidate drug, tafoxiparin, a,new drug ... promising results of the Phase II trial bring the ... strategy. , Dilafor,s candidate drug, ...
Cached Biology Technology:263 Regulatory Professionals Achieve RAC Certification 2263 Regulatory Professionals Achieve RAC Certification 3Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government 2Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government 3Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial 2Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial 3
(Date:7/24/2014)... 2014) Scientists at The New York Stem ... closer to creating a viable cell replacement therapy ... , For the first time, NYSCF scientists ... skin samples of patients with primary progressive multiple ... to induce these stem cells into becoming oligodendrocytes, ...
(Date:7/24/2014)... York, NY - July 24, 2014 -- Keryx Biopharmaceuticals, ... from the long-term, randomized, active control Phase 3 study ... iron-based phosphate binder, for the treatment of hyperphosphatemia in ... PERFECTED study (PhosphatE binding and iRon delivery with FErric ... Journal of the American Society of Nephrology ...
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2
... Hopkins scientists seems to have discovered an almost-too-easy way to ... potent versions. Their finding, reported this week in Nature, could ... but also other body tissues. What the researchers ... neural stem cells the sort that might be used ...
... The giant panda is not at an evolutionary dead end ... new research involving scientists from Cardiff University. Previous ... requirements and slow reproductive rates have led to a lack ... extinction. Now a study by Professor Michael Bruford ...
... August 23, 2007 On August 16, the Food and ... sold under the brand name Coumadin. The new label suggests ... be safer for patients with variations in two genes, CYP2C9 ... testing, which may be a useful tool in determining appropriate ...
Cached Biology News:When is a stem cell not really a stem cell? 2American College of Medical Genetics responds to new FDA labeling decision for warfarin 2
Request Info...
supplied with 10x reaction buffer...
... from yeast/leuconostoc overproducer ATP: ... EC 2.7.1.1/1.1.1.49. One unit of ... of D-glucose in 1 min ... One unit of G6P-DH will ...
Request Info...
Biology Products: